BI 811283
chemical compound
≈ 2 min read
BI 811283. encyclopegia.org, snapshot bi-811283-552277-e9edf07139f8496c. /a/bi-811283
Names in other languages
- EnglishBI 811283
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BI 811283 is a small molecule inhibitor of the Aurora B kinase protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. BI 811283 is currently in the early stages of clinical development and is undergoing first in human trials in patients with solid tumors and acute myeloid leukemia.
Clinical Uses
BI 811283 is currently undergoing investigation in phase 1 and 2 trials and has yet to be licensed by the FDA. BI 811283 may be active in a range of malignancies that are known to have raised levels of Aurora B kinase including; non-small cell lung, brain, head and neck, colorectal and ovarian cancer, where it is associated with worse treatment outcome and poorer overall survival.
Further phase 1 and 2 trials are underway investigating the use of BI 811283 in patients with different types of advanced solid tumours and Acute Myeloid Leukaemia.
Adverse effects
Traditional anti-cancer agents that block cell division commonly cause severe adverse effects. BI 811283 has been developed to selectively target dividing cells, therefore reducing the severity of adverse effects experience by patients.
The most common and severe side effect experienced with BI 811283 is a reduction in the number of white blood cells (leucopenia and neutropenia) which occurs in between 17-42% of patients and can increase the risk of infections and fever.
Studies
Pre-clinical studies have demonstrated that BI 811283 selectively binds to and inhibits the Aurora B kinase protein leading to inhibition of growth and senescence in lung cancer cells in vitro. Furthermore, BI 811283 also inhibits the growth of pancreatic, colorectal and non-small cell lung cancer cells in vivo leading to tumour shrinkage.
First in man clinical trials have demonstrated that BI 811283 is safe and stable in the blood stream. Two early clinical trials have reported that BI 811283 has anti-tumour activity, preventing the progression of cancer in between 29-33% of patients with advanced solid tumours.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329964867 under CC BY-SA 4.0; modifications have been made.